GlaxoSmithKline (GSK)

44.38 +0.10  +0.23%  May 29, 5:19PM Go Pro
You must be signed in to use watchlists.
Sign In or Register
Watch this stock

GlaxoSmithKline Total Return Price: 44.38

Get Interactive Chart for


of


Select a metric
 
Date range: to
<Embed Chart> Pro Save as Image Pro Data Export
Copy the code below and paste
into the embed destination.
  Done
Attention OK

GSK Total Return Price Range, Past 5 Years

Minimum 22.93 Mar 9 2009
Maximum 46.73 Apr 20 2012
Average 36.41

About Total Return Price

Total return price is a theoretical price that helps investors look at their returns over time, accounting for both price appreciation and dividends received rather than price alone. It is the best way to calculate the actual returns on a stock over a period of time.

YCharts' total return price assumes that all dividends were reinvested and that no taxes were collected on dividend payments. This follows Center for Research in Security Prices (CRSP) methodology.

When calculating the return on an investment, an investor should look both at the changes in the value of the stock price as well as the gains from dividend payments. For example, if you buy a stock for $10, its price appreciates to $15 and it pays a $1 dividend, and you sell it, you have made $5 from the change in price and $1 from dividends. This $6 increase is your total gain, and your total return is 60%.

The total return price helps you to look backward to determine an equivalent price that you would have paid to get the same returns from a stock that paid no dividends (also adjusted for splits). Let's look at the previous example again.

Assumptions:
Price paid (1/1/01): $10.00
Closing price (12/30/01): $15.00
Dividend Paid (12/31/01): $1.00
Closing Price (12/31/01): $15.00

Your total returns for the year: $6.00 or 60%

Calculating Total Return Price:

12/31/01:
Actual Price: $15.00
Total Return Price: $15.00
The most recent total return price is always equal to the current price.

12/30/01:
Actual Price: $15.00
Total Return Price: $14.00 = $15.00 x (1-$1/$15.00)
The $1 dividend was 1/15 of the value of the stock, so if you could have received the dividend immediately after buying the stock on 12/30/01, you could have paid $14 for the stock and had a stock worth $15 because of the dividend that was paid.

1/1/01:
Actual Price: $10.00
Total Return Price: $9.33 = $10 x (1-$1/$15.00)
This is exactly like the previous problem. We received 1/15th of the stock's value on 12/30/01, so looking back we need to remove this value from the historical total returns price.
Learn More

You may also be interested in these GSK related companies

Display in Live Stream: Done
Options

GSK News

@mydanilo It had nothing to do with those news. That was already priced in. Seems like Patent news regarding $TEVA and $GSK was the trigger.
about 7 hours ago by mitrado
$AMRN up following news that $Teva and $PRX lost a bid to sell the generic form of $GSK Lovaza. http://stks.co/41F0
about 8 hours ago by abubnic
Auxilium Pharma Sues Watson
May 29, 12:45PM
Teva Issues 2012 Outlook
May 29, 11:00AM
4 Stocks Buffett May Be Buying in Europe
May 25, 12:21PM Investor Place
Finding a Pathway to Approval
May 24, 2:53PM Fool
$GSK reacts to $HGSI poison pill. Stubborn, or what? It seems they do not want to get pushed or pulled.
about 7 days ago by OysterX
20 Giants for a 6% Dividend Yield
May 21, 9:07AM Fool
@xjun &quot;totally betrayed&quot; $AMRN says: &quot;Sorry, it&#39;s not personal. Look at some of my neighbours: $ONTY, $SPPI, $NVAX, $GSK, $TEVA, $CELG ...&quot;
about 12 days ago by mitrado
Why U.K. Bonds Are for Losers
May 17, 6:07PM Fool
Still think that $GSK will not succeed with $HGSI takeover at 13/share. They will increase the offer price, but probably not above 15.
about 13 days ago by OysterX
News related to $GSK, currently 0.0% since open: &#39;Prestige Brands posts small fiscal 4Q loss&#39; http://stks.co/3s9V
about 13 days ago by TradeBot
Gilead Sciences’ HIV Drugs Clear a Hurdle
May 17, 10:00AM Investor Place
$GSK Trametinib also in the spotlight at ASCO &#39;12 with six presentations over 4 days. http://stks.co/3roL
about 13 days ago by abubnic
$GSK Dabrafenib getting its share of attention at ASCO &#39;12 with 50 presentations over 4 days. http://stks.co/3roI
about 13 days ago by abubnic
$PFE $LLY $GSK So this is the condition some drug commercials warned us about! And we thought they were kidding. http://stks.co/3q2n
about 14 days ago by laughing_stock
Don&#39;t see $XNPT popping 100% like $ARNA did, not as glamorous and still has to settle with $GSK. They would get 10 million if still partnrd
about 14 days ago by Glopolon
5 Dividends to Reinvest
May 14, 10:34AM Fool
$ARNA -Big brand name companies may be interested in buyout $GSK $PFE $SNY $ABT First weight-loss drug in US may be approved in June $SPY $$
about 16 days ago by peterumble
$XNPT, No Debt, Drug has already been approved for RLS, so safety issues known. Court case with $GSK still out there, want settlement.
about 18 days ago by Glopolon
Some really tempting European stocks that pay healthy dividends $SNY $HBC $SI $ABB $SNY $GSK $RDS.B all above 4%
about 20 days ago by sld1986
$VVUS Racked With Losses, Vivus is Putting All Its Eggs in This Basket http://stks.co/3kNz $OREX $ARNA $PFE $LLY $GSK
about 20 days ago by DrNick
RT @JasonMilano8 $AMRN Here is a news about current CEO of Amarin selling his former company Reliant to ($GSK) in 2007: http://stks.co/3k0G
about 21 days ago by JasonMilano8
Breakfast Links | via @PointsnFigures http://stks.co/3jto $AMZN $GSK $HGSI $ZNGA
about 21 days ago by STNet
That&#39;s a surprise. $GSK goes hostile with $HGSI offer at 13. Did not expect that and am curious whether HGSI has something up its sleeve.
about 21 days ago by OysterX
$AMRN Here is a news about current CEO of Amarin selling his former company Reliant to GlaxoSmithKline ($GSK) in 2007: http://stks.co/3jYt
about 21 days ago by JasonMilano8
$XNPT, Only non-dopaminergic option for RLS, is the advantage over generics. If $XNPT can work things out with $GSK, this should be $5+
about 21 days ago by Glopolon
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 22 days ago by abubnic
@BioRunUp @GantosJ $XNPT, Hope that they can settle w/ $GSK, and if Astellas in Japan is competent, then $XNPT is looking good.
about 22 days ago by Glopolon
$XNPT Sounds like Astellas is going to be better partner than $GSK, Hope they can work things out with $GSK re: Horizant.
about 23 days ago by Glopolon
$XNPT $GSK, FDA PDUFA date June 9th for Horizant treating postherpetic neuralgia. Horizant already approved in Japan for restless leg synd.
about 26 days ago by Glopolon
Best Yielding Large Cap Healthcare Stocks + http://stks.co/3cMJ + $JNJ $PFE $NVS $MRK $GSK $SNY $NVO $UNH $BMY $TEVA $MDT $BAX $AGN $SYK
about 28 days ago by DividendYield

Recent Quotes

Symbol Price Chg Chg % Market Cap
GSK 44.38 +0.10 +0.23% 111.75B
GSIT 4.18 -0.02 -0.48% 120.25M
GSIG 11.98 +0.13 +1.10% 397.09M
GSI 0.9874 +0.12 +13.48%
GSH 16.41 +0.11 +0.67% 2.314B
GSB 2.06 -0.09 -4.19% 39.15M
GSAT 0.391 -0.01 -3.43% 120.61M
GS 97.82 +1.12 +1.16% 47.86B
GRZ 3.40 +0.11 +3.34% 195.89M
GRX 8.14 +0.04 +0.49%
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close